Bone marrow transplantation in hindlimb muscles of motoneuron degenerative mice reduces neuronal death and improves motor function

Stem Cells and Development

Volumn 22, Issue 11, 2013, Pages 1633-1644

  Pastor, Diego ^a   Viso León, Mari Carmen ^a   Botella López, Arancha ^a   Jaramillo Merchan, Jesus ^a   Moraleda, Jose M ^b   Jones, Jonathan ^a   Martínez, Salvador ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEURITE PROMOTING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CONTROLLED STUDY; HINDLIMB MUSCLE; INNERVATION; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; MOUSE; NERVE CELL NECROSIS; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SPINAL CORD; SURVIVAL RATE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEINS; HINDLIMB; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR NEURONS; MUSCLE, SKELETAL; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; RECOVERY OF FUNCTION; SPINAL CORD;

EID: 84878067148     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0487     Document Type: Article

References (52)

1. Turner BJ, SS Murray, LG Piccenna, EC Lopes, TJ Kilpatrick and SS Cheema. (2004). Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. J Neurosci Res 78:193-199.
2. Phukan J and O Hardiman. (2009). The management of amyotrophic lateral sclerosis. J Neurol 256:176-186.
3. Coleman MP and VH Perry. (2002). Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532-537.
4. Suzuki M, J McHugh, C Tork, B Shelley, SM Klein, PA Ebischer and CN Svendsen. (2007). GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2:e689.
5. Fischer LR, DG Culver, P Tennant, AA Davis, M Wang, A Castellano-Sanchez, J Khan, MA Polak and J Glass. (2004). D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185:232-240.
6. Nagano I, M Shiote, T Murakami, H Kamada, Y Hamakawa, E Matsubara, M Yokoyama, K Moritaz, M Shoji and K Abe. (2005). Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 27:768-772.
7. Storkebaum E, D Lambrechts, M Dewerchin, MP Moreno-Murciano, S Appelmans, H Oh, P Van Damme, B Rutten, WY Man, et al. (2005). Treatment of motoneurondegeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8:85-92.
8. Wang Y, XO Mao, L Xie, S Banwait, HH Marti, DA Greenberg and K Jin. (2007). Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 27: 304-307.
9. Henderson CE, HS Phillips, RA Pollock, AM Davies, C Lemeulle, M Armanini, L Simmons, B Moffet, RA Vandlen, VE Koliatsov and A Rosenthal. (1994). GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266:1062-1064.
10. Oppenheim RW, LJ Houenou, JE Johnson, LF Lin, L Li, AC Lo, AL Newsome, DM Prevette and S Wang. (1995). Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 373:344-346.
11. Yan Q, C Matheson and OT Lopez. (1995). In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 373:341-344.
12. Cabanes C, S Bonilla, L Tabares and S Martinez. (2007). Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis 26:408-418.
13. Treanor JJ, L Goodman, F de Sauvage, DM Stone, KT Poulsen, CD Beck, C Gray, MP Armanini, RA Pollock, et al. (1996). Characterization of a multicomponent receptor for GDNF. Nature 382:80-83.
14. Airaksinen MS and M Saarma. (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394.
15. Perrelet D, A Ferri, P Liston, P Muzzin, RG Korneluk and AC Kato. (2002). IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo. Nat Cell Biol 4:175-179.
16. Jones J, J Jaramillo-Merchan, C Bueno, D Pastor, M Viso-Leon and S Martinez. (2010). Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol Dis 40:415-423.
17. Pastor D, MC Viso-Leon, J Jones, J Jaramillo-Merchan, JJ Toledo-Aral, JM Moraleda and S Martinez. (2011). Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model. Stem Cell Rev Rep 8:445-458.
18. Hall ED, JA Oostveen and ME Gurney. (1998). Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23:249-256.
19. Blot S, C Poirier and PA Dreyfus. (1995). The mouse mutation muscle deficient (mdf) is characterized by a progressive motoneuron disease. J Neuropathol Exp Neurol 54:812-825.
20. Poirier C, S Blot, M Fernandes, GF Carle, V Stanescu, R Stanescu and JL Guenet. (1998). A high-resolution genetic map of mouse chromosome 19 encompassing the muscledeficient osteochondrodystrophy (mdf-ocd) region. Mamm Genome 9:390-391.
21. Schmidt WM, C Kraus, H Hoger, S Hochmeister, F Oberndorfer, M Branka, S Bingemann, H Lassmann, M Muller, et al. (2007). Mutation in the Scyl1 gene encoding amino-terminal kinase-like protein causes a recessive form of spinocerebellar neurodegeneration. EMBO Rep 8:691-697.
22. Okabe M, M Ikawa, K Kominami, T Nakanishi and Y Nishimune. (1997). 'Green mice' as a source of ubiquitous green cells. FEBS Lett 407:313-319.
23. Sanchez MP, I Silos-Santiago, J Frisen, B He, SA Lira and M Barbacid. (1996). Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382:70-73.
24. McGavern DB, L Zoecklein, KM Drescher and M Rodriguez. (1999). Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination. Exp Neurol 158:171-181.
25. Kaspar BK, LM Frost, L Christian, P Umapathi and FH Gage. (2005). Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. Ann Neurol 57:649-655.
26. Kayatekin BM, S Gonenc, O Acikgoz, N Uysal and A Dayi. (2002) Effects of sprint exercise on oxidative stress in skeletal muscle and liver. Eur J Appl Physiol 87:141-144.
27. Suzuki M, J McHugh, C Tork, B Shelley, A Hayes, I Bellantuono, P Aebischer and CN Svendsen. (2008). Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 16:2002-2010.
28. Bonilla S, A Silva, L Valdes, E Geijo, JM Garcia-Verdugo and S Martinez. (2005). Functional neural stem cells derived from adult bone marrow. Neuroscience 133:85-95.
29. Fischer LR and JD Glass. (2007). Axonal degeneration in motor neuron disease. Neurodegener Dis 4:431-442.
30. Sagot Y, T Rosse, R Vejsada, D Perrelet and AC Kato. (1998). Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease. J Neurosci 18:1132-1141.
31. Kaspar BK, J Llado, N Sherkat, JD Rothstein and FH Gage. (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839-842.
32. Ozdinler PH and JD Macklis. (2006). IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 9:1371-1381.
33. Kanda T, T Iwasaki, S Nakamura, A Ueki, T Kurokawa, K Ikeda and H Mizusawa. (1999). FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons. Int J Dev Neurosci 17:191-200.
34. Haase G, P Kennel, B Pettmann, E Vigne, S Akli, F Revah, H Schmalbruch and A Kahn. (1997). Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 3:429-436.
35. Haase G, B Pettmann, T Bordet, P Villa, E Vigne, H Schmalbruch and A Kahn. (1999). Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuronopathy depends on the route of delivery. Ann Neurol 45: 296-304.
36. Bordet T, JC Lesbordes, S Rouhani, L Castelnau-Ptakhine, H Schmalbruch, G Haase and A Kahn. (2001). Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum Mol Genet 10:1925-1933.
37. Greenberg DA and K Jin. (2004). VEGF and ALS: the luckiest growth factor? Trends Mol Med 10:1-3.
38. Lambrechts D, E Storkebaum and P Carmeliet. (2004). VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol Med 10:275-282.
39. Suzuki M and CN Svendsen. (2008). Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 31:192-198.
40. Keller-Peck CR, G Feng, JR Sanes, Q Yan, JW Lichtman and WD Snider. (2001). Glial cell line-derived neurotrophic factor administration in postnatal life results in motor unit enlargement and continuous synaptic remodeling at the neuromuscular junction. J Neurosci 21:6136-6146.
41. Lie DC and J Weis. (1998). GDNF expression is increased in denervated human skeletal muscle. Neurosci Lett 250:87-90.
42. Kust BM, JC Copray, N Brouwer, D Troost and HW Boddeke. (2002). Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol 177:419-427.
43. Grundstrom E, H Askmark, J Lindeberg, I Nygren, T Ebendal and SM Aquilonius. (1999). Increased expression of glial cell line-derived neurotrophic factor mRNA in muscle biopsies from patients with amyotrophic lateral sclerosis. J Neurol Sci 162:169-173.
44. Lu P, LL Jones, EY Snyder and MH Tuszynski. (2003). Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 181:115-129.
45. Guillot S, M Azzouz, N Deglon, A Zurn and P Aebischer. (2004). Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis 16:139-149.
46. Li W, D Brakefield, Y Pan, D Hunter, TM Myckatyn and A Parsadanian. (2007). Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol 203:457-471.
47. Manabe Y, I Nagano, MS Gazi, T Murakami, M Shiote, M Shoji, H Kitagawa, Y Setoguchi and K Abe. (2002). Adeno-virus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Apoptosis 7:329-334.
48. Yamamoto M, Y Ito, N Mitsuma, M Li, N Hattori and G Sobue. (2002). Parallel expression of neurotrophic factors and their receptors in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 25:601-604.
49. Manabe Y, I Nagano, MS Gazi, T Murakami, M Shiote, M Shoji, H Kitagawa and K Abe. (2003). Glial cell line-derived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Neurol Res 25:195-200.
50. Wang LJ, YY Lu, S Muramatsu, K Ikeguchi, K Fujimoto, T Okada, H Mizukami, T Matsushita, Y Hanazono, et al. (2002). Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 22:6920-6928.
51. Bretzner F and T Drew. (2005). Changes in corticospinal efficacy contribute to the locomotor plasticity observed after unilateral cutaneous denervation of the hindpaw in the cat. J Neurophysiol 94:2911-2927.
52. Nishimura Y and T Isa. (2012). Cortical and subcortical compensatory mechanisms after spinal cord injury in monkeys. Exp Neurol 235:152-161.